Abstract
We evaluated response to a single dose of the FINLAY-FR-1A recombinant dimeric-RBD base vaccine during a phase I clinical trial with 30 COVID-19 convalescents, to test its capacity for boosting natural immunity. This short report shows: a) an excellent safety profile one month after vaccination for all participants, similar to that previously found during vaccination of naïve individuals; b) a single dose of vaccine induces a >20 fold increase in antibody response one week after vaccination and remarkably 4-fold higher virus neutralization compared to the median obtained for Cuban convalescent serum panel. These preliminary results prompt initiation of a phase II trial in order to establish a general vaccination protocol for convalescents.
Competing Interest Statement
Finlay Vaccine Institute and Center for Molecular Immunology has filed patent applications relating to use vaccination in individuals with preexisting immunity SARS-CoV-2
Clinical Trial
IFV/COR/07 RPCE00000349
Clinical Protocols
https://rpcec.sld.cu/trials/RPCEC00000349
Funding Statement
This work was partially funded by Fondo de Ciencia e Innovacion (FONCI) from the Ministry of Science and Enviroment of Cuba (Project-2020-20)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Independent Ethical Committee for the Study of Human Subjects in the Institute of Hematology and Immunology
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will b e available at https://rpcec.sld.cu/trials/RPCEC00000349 or under request to author
